Inflammatory bowel disease (IBD) is an intractable disease and is one of the most numerous diseases designated by the Ministry of Health, Labour and Welfare (MHLW). Previously, it was very difficult to maintain remission because of few therapeutic agents. In recent years, an increasing number of drugs with different targeted agents covered by social insurance has expanded the range of therapeutic options. Furthermore, the availability of several similarly targeted drugs with the same effect has increased the number of choices but has also raised a further issue of difficulty in selecting the most appropriate treatment. Due to the long disease duration, treatment strategies aimed at maintaining long-term remission are required, considering the various life events of individual patients, such as education, working, childbirth and childcare. This session will provide an opportunity to discuss how to overcome the challenges of selecting and optimizing treatment for an ever-diversifying patient population, to understand the current situation and to share future perspectives.